Cancer drug nivolumab tested in rare blood cancer
NCT ID NCT06936943
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests the drug nivolumab (Opdivo) in 14 people with Richter's transformation, a rare and aggressive blood cancer that arises from chronic lymphocytic leukemia. The study measures how many patients respond to treatment, how long they live, and safety. All participants receive nivolumab every 4 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nivolumab (Opdivo)
- What this could lead to
- If it works, this could offer a new treatment option for Richter's transformation, a rare and aggressive blood cancer.
- What could go wrong
- This is a small, early-phase study with only 14 participants, so results may not apply broadly. Nivolumab can cause immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RICHTER'S TRANSFORMATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aichi Cancer Center
RECRUITINGNagoya, Aichi-ken, Japan
-
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
RECRUITINGHiroshima, Hiroshima, Japan
-
Hokkaido University Hospital
RECRUITINGSapporo, Hokkaido, 060-8648, Japan
-
Kindai University Hospital
RECRUITINGŌsaka-sayama, Osaka, Japan
-
Kyoto University Hospital
RECRUITINGKyoto, Kyoto, Japan
-
Kyusyu University Hospital
RECRUITINGFukuoka, Fukuoka, 812-8582, Japan
-
National Cancer Center Hospital
RECRUITINGChuo Ku, Tokyo, Japan
-
Niigata University Medical & Dental Hospital
RECRUITINGNiigata, Niigata, Japan
-
Tohoku University Hospital
RECRUITINGSendai, Miyagi, Japan
-
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
RECRUITINGBunkyō-Ku, Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which Pre-CAR-T chemo is safer? new trial aims to find out
- New drug targets Hard-to-Treat blood cancers in chinese trial
- Engineered cells take on hard-to-treat blood cancers in early trial
- New hope for aggressive blood cancer: drug combo trial opens
- New pill takes on hard-to-treat blood cancers in early trial
- Massive new registry to track thousands of blood cancer patients for years